期刊文献+

去氢表雄酮衍生物的合成及其抑制神经炎症活性研究 被引量:1

Synthesis and their inhibitory activities of neuroinflammation of dehydroepiandrosterone derivatives
原文传递
导出
摘要 目的设计合成一系列去氢表雄酮衍生物,通过对抑制脂多糖(LPS)诱导小胶质细胞激活作用的筛选,以期发现具有抗神经炎症活性的化合物。方法以去氢表雄酮或15β,16β-环丙烷-去氢表雄酮为起始原料,在C-3位β羟基上通过成酯缩合的方法引入天然构型的氨基酸片段,并结合化学合成和生物发酵手段,对C-7位、C-4位进行氧化合成目标化合物;建立了小胶质细胞系BV-2细胞模型,通过LPS的刺激,以抑制一氧化氮(NO)释放量为检测指标,测试化合物的体外抗炎作用,并结合MTT实验检测化合物的细胞毒性。结果与结论通过对相关文献方法的改进和优化,合成了16个目标化合物,其结构经核磁共振氢谱、质谱确证;对小胶质细胞LPS诱导炎症反应抑制作用的活性测试结果表明,在20μmol·L-1时绝大部分目标化合物对一氧化氮的释放有较好的抑制作用,但是具有15β,16β-环丙烷结构的化合物基本都丧失了对NO释放的抑制作用,而具有双羟基结构的目标化合物(9和10)在保持很低的细胞毒性的情况下,对NO的释放抑制作用略有提高,并且呈现剂量依赖性。相关构效关系及作用机制值得进一步研究。 Glial activation mediated neuroinflammation plays a pivotal role in the process of several neuroinflammatory diseases including stroke,Alzheimer' s diseases,Parkinson' s diseases,multiple sclerosis and ischemia. Inhibition of microglial activation may ameliorate neuronal degeneration under the inflammatory conditions. In the present study,a series of dehydroepiandrosterone derivatives were designed and synthesized. The anti-inflammatory effects of these compounds were evaluated using LPS-stimulated BV-2 microglia cells. Those derivatives were prepared from readily available dehydroepiandrosterone and its downstream product 15β,16β-cyclopropane-dehydroepiandrosterone incorporating amino acid methyl esters at C-3hydroxyl group,and oxidation at C-4 or C-7 position. Among all the 16 compounds,several analogs exhibited potent inhibitory activities on nitric oxide production( inhibition rate 75%) with no or weak cell toxi city at 20 μmol·L- 1. The related SARs and function mechanism is worth further research and discussion.
出处 《中国药物化学杂志》 CAS CSCD 2016年第5期353-360,共8页 Chinese Journal of Medicinal Chemistry
关键词 去氢表雄酮 神经炎症 一氧化氮 氨基酸 dehydroepiandrosterone neuroinflammation nitric monoxide(NO) amino acid
  • 相关文献

参考文献3

二级参考文献67

  • 1江敏,崔鹏,于涛,杨帆,汤杰.3β-羟基雄甾-4-烯-6,17-二酮的合成[J].应用化学,2006,23(12):1422-1424. 被引量:2
  • 2PARDRIDGE W M. Blood-brain barrier delivery [ J ]. Drug Discov Today,2007,12 (1/2) :54 - 61.
  • 3PARDRIDGE W M. Why is the global CNS pharma- ceutical market so undcrpenetrated? [ J ]. Drug Dis- cov Toclay,2002,7(1) :5-7.
  • 4PARDRIDGE W M. The blood-brain barrier: bottle- neck in brain drug development [ J ]. Neuro Rx, 2005, 2(1) :3 -14.
  • 5PARDRIDGE W M. Blood-brain barrier drug targe- ring:the future of brain drug development[ J]. Mol Interv,2003,3(2) :90 - 105.
  • 6LEE G,DALLAS S,HONG M,et al. Drug transport- ers in the central nervous system:brain barriers and brain parenchyma[ J ]. Pharm Rev, 2001,53 ( 4 ) : 569 - 596.
  • 7JEANNERET L J, SCHMITT F. Chemical modifica- tion of therapeutic drugs or drug vector systems to achieve targeted therapy: looking for the grail [ J ]. Med Res Rev,2007,27(4) :574 -590.
  • 8RAUTIO J, LAINE K, GYNTI-IER M, et al. Prodrug approaches for CNS delivery[ J ]. AAPS J,2008,10 ( 1 ) :92 - 102.
  • 9KERNS E H, DI L. Drug-like properties: concepts, structure design and methods:from ADME to toxici- ty optimization [ M ]. UK: Elsevier Inc, 2008: 122 - 136.
  • 10PARDRIDGE W M. CNS drug design based on prin- ciples of blood-brain barrier transport [ J ]. J Ncuro- chem, 1998,70 (5) : 1781 - 1792.

共引文献13

同被引文献14

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部